Anext
Latest round
- Series A
Last raised
- Dec 2024
Total raised
- Undisclosed
Investors
- 2
About Anext
Founded in 2013 in Shanghai, China, Anext operates as a biotechnology company that focuses on the development of anti-aging and anti-aging stem cell therapy products. It was recognized as the National High-tech Enterprise. The company has applied for 33 patents, with 16 software copyrights. Its clinical-grade mesenchymal stem cell exosomes were approved by the FDA. The company is mainly engaged in the research and development of anti-aging and anti-aging stem cell therapy products. The company has mastered technologies such as the exosome cell repair drug ANEXT Smart EX and the exosome drug delivery carrier ANEXT Super Delivery. The main product is clinical-grade mesenchymal stem cell exosomes. The target customers of the company are healthcare providers, research institutions, and cosmetic companies. The company generates revenue by providing anti-aging and anti-aging stem cell therapy products.
Who invested in Anext
2 investors across 1 round
See all investors in Anext
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 14, 2024
Amount
Undisclosed
Investors
Questions about Anext
Who invested in Anext?
Anext has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Anext raised?
Anext has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Anext last raise money?
Anext's most recent round on record is a Series A, in Dec 2024.
What does Anext do?
Founded in 2013 in Shanghai, China, Anext operates as a biotechnology company that focuses on the development of anti-aging and anti-aging stem cell therapy products.
Where is Anext headquartered?
Anext is headquartered in Shanghai, China.
Which VCs invest in companies like Anext?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Anext's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Anext? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.